Current Colorectal Cancer Reports

, 1:91

Individualized chemotherapy based on genetic and genomic profiling

  • Syma Iqbal
  • Heinz-Josef Lenz

DOI: 10.1007/s11888-005-0005-4

Cite this article as:
Iqbal, S. & Lenz, HJ. Curr colorectal cancer rep (2005) 1: 91. doi:10.1007/s11888-005-0005-4


The treatment of colorectal cancer has evolved over the past few years to multidrug therapy including 5-fluouracil (5-FU), irinotecan (CPT-11), and oxaliplatin combination regimens. The addition of novel agents such as bevacizumab and cetuximab has added to the efficacy of chemotherapy in this disease. Identification of molecular determinants of 5-FU, irinotecan, and oxaliplatin efficacy and toxicity is of critical importance for the development of more efficient and less toxic treatment strategies for patients with colon cancer. Markers have been identified that may predict response, survival and toxicity to 5-FU, CPT-11, and platinum-based chemotherapy in patients with advanced colorectal cancer. This review explores these markers as well as potential new markers that have been identified for irinotecan and targeted therapy.

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Syma Iqbal
  • Heinz-Josef Lenz
    • 1
  1. 1.University of Southern California/Norris Comprehensive Cancer CenterLos AngelesUSA